5-HT2A receptor polymorphism may modulate antipsychotic treatment response in Alzheimer's disease

Int J Geriatr Psychiatry. 2004 Nov;19(11):1108-9. doi: 10.1002/gps.1179.

Authors

Sebastiaan Engelborghs¹, Clive Holmes, Michelle McCulley, Peter P De Deyn

Affiliation

¹ Department of Neurology and Memory Clinic, Middelheim General Hospital, ZNA, and Laboratory of Neurochemistry and Behaviour, Born-Bunge Foundation, University of Antwerp, Antwerp, Belgium.

PMID: 15497194
DOI: 10.1002/gps.1179

No abstract available

Publication types

Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Alzheimer Disease / drug therapy*
Alzheimer Disease / genetics*
Antipsychotic Agents / therapeutic use*
Female
Humans
Male
Pilot Projects
Polymorphism, Genetic*
Receptor, Serotonin, 5-HT2A / genetics*
Treatment Outcome

Substances

Antipsychotic Agents
Receptor, Serotonin, 5-HT2A